Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

If you’re wondering what’s next for Teva Pharmaceutical Industries (NYSE:TEVA), the company’s latest move might catch your ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.

The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday.

Investing.com -- Teva Pharmaceutical Industries Ltd ADR (NYSE:TEVA) stock rose 2.7% after the company announced FDA approval and U.S. launch of its generic version of Saxenda (liraglutide injection), ...

The Food and Drug Administration is cracking down on ingredients from potentially from unverified foreign sources and that ...

Idaho’s health insurance plan for state employees will stop covering prescription medication for weight loss on Nov. 1. In a ...

Arrowhead Pharmaceuticals and Novartis agreed to a deal worth up to $2 billion for a license to a neuromuscular therapy. Remedy Meds is set to acquire Thirty Madison for just over $500 million.